Cure8 research brief
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For ulcerative colitis, predictors were not identified in this study.
Adults with Crohn’s disease or ulcerative colitis, patients currently on or considering ustekinumab, IBD clinicians managing biologic therapy, and researchers studying dose optimization and TDM.
This was a retrospective cohort of 206 adults (165 CD, 41 UC) treated with ustekinumab. Dose escalation occurred in 41.8% of CD and 34.1% of UC patients, with median time to escalation of 9 months (CD) and 4.5 months (UC).
Multivariable analysis in CD found prior biologic use and prior immunomodulator use were associated with escalation; similar predictors were not seen in UC.
How people might use this Patients and clinicians can view these findings as hypothesis-generating evidence that treatment history and disease duration may help identify people with CD at higher risk of needing intensified ustekinumab dosing.
The authors note prospective studies including therapeutic drug monitoring and standardized escalation protocols are needed. More on the source The article is a peer-reviewed journal abstract/full text in Frontiers in Pharmacology presented as a retrospective real-world cohort (structured content depth: abstract).
The findings describe associations and do not establish causation.
Retrospective real-world design can identify associations but is limited by potential confounding. The authors highlight the need for prospective studies that include therapeutic drug monitoring and standardized escalation rules. This brief is based on the article abstract/full text provided; it does not represent independent review of the full dataset.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
